438 related articles for article (PubMed ID: 22496332)
1. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Sotgiu G; Centis R; D'Ambrosio L; Alffenaar JW; Anger HA; Caminero JA; Castiglia P; De Lorenzo S; Ferrara G; Koh WJ; Schecter GF; Shim TS; Singla R; Skrahina A; Spanevello A; Udwadia ZF; Villar M; Zampogna E; Zellweger JP; Zumla A; Migliori GB
Eur Respir J; 2012 Dec; 40(6):1430-42. PubMed ID: 22496332
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
De Lorenzo S; Alffenaar JW; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Bolhuis MS; van Altena R; Viggiani P; Piana A; Spanevello A; Migliori GB
Eur Respir J; 2013 Jun; 41(6):1386-92. PubMed ID: 22997218
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand.
Roongruangpitayakul C; Chuchottaworn C
J Med Assoc Thai; 2013 Oct; 96(10):1273-82. PubMed ID: 24350407
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
5. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
Migliori GB; Eker B; Richardson MD; Sotgiu G; Zellweger JP; Skrahina A; Ortmann J; Girardi E; Hoffmann H; Besozzi G; Bevilacqua N; Kirsten D; Centis R; Lange C;
Eur Respir J; 2009 Aug; 34(2):387-93. PubMed ID: 19282348
[TBL] [Abstract][Full Text] [Related]
6. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.
Koh WJ; Kang YR; Jeon K; Kwon OJ; Lyu J; Kim WS; Shim TS
J Antimicrob Chemother; 2012 Jun; 67(6):1503-7. PubMed ID: 22403262
[TBL] [Abstract][Full Text] [Related]
7. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations.
Garcia-Prats AJ; Rose PC; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2014 Mar; 94(2):93-104. PubMed ID: 24388605
[TBL] [Abstract][Full Text] [Related]
8. Linezolid in the treatment of multidrug-resistant tuberculosis.
Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
[TBL] [Abstract][Full Text] [Related]
9. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
[TBL] [Abstract][Full Text] [Related]
10. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
[TBL] [Abstract][Full Text] [Related]
11. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.
Cox H; Ford N
Int J Tuberc Lung Dis; 2012 Apr; 16(4):447-54. PubMed ID: 22325685
[TBL] [Abstract][Full Text] [Related]
12. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India.
Singla R; Caminero JA; Jaiswal A; Singla N; Gupta S; Bali RK; Behera D
Eur Respir J; 2012 Apr; 39(4):956-62. PubMed ID: 21965225
[TBL] [Abstract][Full Text] [Related]
13. Linezolid in the treatment of MDR-TB: a retrospective clinical study.
Xu HB; Jiang RH; Li L; Xiao HP
Int J Tuberc Lung Dis; 2012; 16(3):358-63. PubMed ID: 22640450
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil.
Arbex MA; Bonini EH; Kawakame Pirolla G; D'Ambrosio L; Centis R; Migliori GB
Rev Port Pneumol (2006); 2016; 22(6):337-341. PubMed ID: 27481315
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.
Agyeman AA; Ofori-Asenso R
Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):41. PubMed ID: 27334498
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Abdo Arbex M; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Auchynka V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Jun; 47(6):1758-66. PubMed ID: 27076583
[TBL] [Abstract][Full Text] [Related]
19. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
Chaiprasert A; Srimuang S; Tingtoy N; Makhao N; Sirirudeeporn P; Tomnongdee N; Theankeaw O; Charoensook S; Leechawengwongs M; Prammananan T
Int J Tuberc Lung Dis; 2014 Aug; 18(8):961-3. PubMed ID: 25199012
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
Tang S; Yao L; Hao X; Zhang X; Liu G; Liu X; Wu M; Zen L; Sun H; Liu Y; Gu J; Lin F; Wang X; Zhang Z
Eur Respir J; 2015 Jan; 45(1):161-70. PubMed ID: 25234807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
